Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis discusses Biolaunch project

Sanofi-Aventis discusses Biolaunch project

6th May 2009

Sanofi-Aventis’ new Biolaunch project will benefit the company by providing a complete platform of expertise in biotechnologies, it has asserted.

It officially launched the programme yesterday (May 5th) at the company’s Vitry-sur-Seine pharmaceuticals production site in France.

As from 2012, the investment of almost 200 million euros (176.8 million pounds) will go towards the business’ first cell culture biotechnology platform to develop monoclonal antibodies.

These should launch a new generation of treatments that have fewer side effects, are more effective and targeted more precisely, explained chief executive officer of the company Christopher A Viehbacher.

He said: “This project, which gathers and mobilises the best expertise both inside and outside the company, is an illustration of the ongoing transforming programme within Sanofi-Aventis.”

Last week, the firm released its first quarter 2009 financial results. Sales of its pharmaceutical division were up three per cent on a constant structure basis and at constant exchange rates.

Net sales of Lovenox increased 1.3 per cent, Lantus rose 27.1 per cent and Plavix grew 3.6 per cent.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.